Histological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy

Similar documents
Oncologist-induced Disease of the GI tract: New Developments

MANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS

What is your diagnosis? a. Lymphocytic colitis. b. Collagenous colitis. c. Common variable immunodeficiency (CVID) associated colitis

INTERNATIONAL COURSE ON THE PATHOLOGY OF THE DIGESTIVE SYSTEM VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY BUCHAREST 7-8 BUCHAREST 2014

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response

Mechanisms of Immune Tolerance

하부위장관비종양성질환의 감별진단 주미인제의대일산백병원

MANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY

Innate immune regulation of T-helper (Th) cell homeostasis in the intestine

HDF Case Whipple s disease

Gender Differences in Autoimmune Diseases

IBD. Crohn s. Outline. Ulcerative colitis versus Crohn s disease: is biopsy useful? UC vs. Crohn s? Is it easy? Biopsy settings 21/07/2017 IBD

What do we need for diagnosis of IBD

Effector T Cells and

Chronic immune colitis in rabbits

Supplemental Digital Content 1. Endoscopic and histolological findings in INR and FR study subjects

GUIDELINES FOR THE INITIAL BIOPSY DIAGNOSIS OF CHRONIC IDIOPATHIC INFLAMMATORY BOWEL DISEASE A STRUCTURED APPROACH TO COLORECTAL BIOPSY ASSESSMENT

Pitfalls in the Diagnosis of Inflammatory Bowel Disease

Case Report Cytomegalovirus Colitis with Common Variable Immunodeficiency and Crohn s Disease

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF

TRICHURIASIS : LOCALIZED INFLAMMATORY RESPONSES IN THE COLON

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs

Fujiya M, Saitoh Y, Watari J, Moriichi K, Kohgo Y.

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

Histopathology: gastritis and peptic ulceration

Original Article. Atypical histological features of ulcerative colitis. Siddharth N Shah, 1 Anjali D Amarapurkar, 1 N Shrinivas, 2 Rathi PM 2 ABSTRACT

SAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST QUESTIONS. Ver. #

11/1/2017. Tetyana Mettler, MD Department of Laboratory Medicine and Pathology University of Minnesota. Cerilli & Greenson

Genetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD

Patterns of Colonic Involvement at Initial Presentation in Ulcerative Colitis A Retrospective Study of 46 Newly Diagnosed Cases

Supplemental Table I.

Frequency and Distribution of Microscopic Findings in Patients with Chronic Non-Bloody Diarrhea and Normal Colonoscopy

The revised Porto criteria for diagnosing

HDF Case CRYPTOSPORIDIOSE

Case History B Female patient 1970 Clinical History : crampy abdominal pain and episodes of bloody diarrhea Surgical treatment

Autoimmunity and Primary Immune Deficiency

What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you)

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology

Chronic Colitis Pattern Christina A. Arnold, M.D. The Ohio State University Wexner Medical Center Columbus, Ohio

Allergic Colitis Clinical and Endoscopic Aspects of Infants. with Rectal Bleeding

IL-12 family members in experimental colitis. Markus F. Neurath I. Medical Clinic Johannes Gutenberg-University Mainz, Germany

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Epstein Barr virus - related diarrhea or exacerbation of inflammatory bowel disease: A diagnostic dilemma

Cathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease. Therapeutic Area Partnerships Presentation.

An autoimmune perspective on neuromuscular diseases

Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011

Supplemental Materials

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

Radiation Therapy as an Immunomodulator

SAM PROVIDER TOOLKIT

Inflammation in the clinic

Gastrooesophageal reflux disease. Jera Jeruc Institute of pathology, Faculty of Medicine, Ljubljana, Slovenia

A Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis

Opportunistic Infections of the Colon in

FcγRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via ipilimumab-dependent ADCC in melanoma patients

January 25, 2017 Scientific Research Process Name of Journal: ESPS Manuscript NO: Manuscript Type: Title: Authors: Correspondence to

BIOPSY DIAGNOSIS OF COLITIS Common and Unusual Forms of Inflammatory Bowel disease

For the past 40 years, it has been standard practice to obtain

Supplementary Figure 1 IL-27 IL

A Practical Approach to Small Bowel Biopsies: All that flattens is not sprue

The pathology of IBD and its modification by liver disease. Roger Feakins ESP/H-ECCO

Biopsy Evaluation of Non- Neoplastic Diseases of the Large Bowel: an algorithmic approach

The Morphologic Profile of Inflammatory Bowel Disease and the Diagnostic Problem of Crohn s Disease versus TB Colitis A Case Series

Emerging Concepts of Cancer Immunotherapy

Murine Models of. Inflammatory Bowel Disease. Outline. Laura P. Hale, M.D. Ph.D. Professor of Pathology Duke University Medical Center

L1 on PyMT tumor cells but Py117 cells are more responsive to IFN-γ. (A) Flow

Kids Like to Break the Rules: Gastrointestinal Pathology in Children

USCAP Pediatric Pathology Speciality Conference Case 3. S.Ranganathan, MD Children s Hospital of Pittsburgh of UPMC 4/13/2016

Supplemental materials

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Q: How should we diagnose and manage

Chapter 12: Training in Pathology. DDSEP Chapter 13: Question 19

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Reviewers' comments: Reviewer #1 (Remarks to the Author):

Tim-3 as a target for tumor immunotherapy

Melanoma gene expression profiles to identify mechanisms of tumor resistance

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA

Mimics of Inflammatory Bowel Disease. Dr Catriona McKenzie Royal Prince Alfred Hospital, Camperdown

Novel anti-inflammatory compounds for ulcerative colitis and rheumatoid arthritis therapy

Management of Incurable Prostate Cancer in 2014

Supplementary Material

Specialespecifikt kursus i Patologisk Anatomi 2009: Fordøjelseskanalens patologi APPENDIX

SUPPLEMENTARY INFORMATION

Selective leucocyte trafficking inhibitors for treatment of IBD

Immunology, Faculty of Medicine University of Bari, Bari (Italy) Proprietà benefiche di latte, vino e olio extra vergine di oliva

Immunotherapy in lung cancer. Saurabh maji

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

ICLIO Webinar: Immuno-Oncology: From a Community Radiologist Perspective Michael J. DeLeo III, MD

Faecalibacterium prausnitzii

Normal small intestine Variations

PATHOLOGY OF NON NEOPLASTIC LESIONS OF THE UPPER GASTROINTESTINAL TRACT.

Small Bowel Cases. Introduction. Introduction, Continued 12/7/2011. Lesions Found on endoscopic biopsies Just Like Signing Out

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

Supplemental Table 1. Primers used for RT-PCR analysis of inflammatory cytokines Gene Primer Sequence

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Exploring Therapeutic Combinations with anti-ctla-4 Antibody

Grup de fisiologia digestiva i adaptacions nutricionals Institut de Nutrició i Seguretat Alimentaria

Transcription:

Histological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy M. Perdiki 2, G. Bamias 1, D. Pouloudi 2, H. Gogas 3, I. Delladetsima 2 1 Academic Dpt. of Gastroenterology, National and Kapodistrian University of Athens, Greece 2 First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Greece 3 First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Greece

There is no conflict of interest

Introduction Immunotherapy increasingly incorporated in the treatment algorithms for malignant neoplasms in recent years Ipilimumab fully human, IgG1, anti-ctla-4 monoclonal antibody Approval for the treatment of metastatic melanoma in 2011, in both US and Europe Treatment of neoplasias with ipilimumab associated with immunemediated adverse reactions, (hypophysitis, thyreoiditis, hepatitis, uveitis) and especially the development of immune-mediated colitis

J Autoimmun. 2013 Sep; 45(100): 49 57.

Aim of the study The evaluation of the histological characteristics of ipilimumabassociated colitis (IAC) in patients with severe diarrhea after treatment for metastatic melanoma The determination of the mucosal immunophenotype 1. mrna expression patterns for the most important effector and regulatory cytokines and transcription factors in comparison to both healthy controls and patients with inflammatory bowel disease (IBD) 2. The composition of lymphocytic cell populations that infiltrate the colonic mucosa in IAC

Material and Methods Examined material: colonic biopsies from 9 patients with severe diarrhea subsequent to initiation of ipilimumab therapy for metastatic melanoma Control groups: 8 healthy individuals and 9 naive IBD cases

Material and Methods Histological examination included Inflammatory infiltrates Number of neutrophils and eosinophils Erosions/ulcerations Crypts with flattened mucin depleted epithelium Cryptitis Crypt abscesses Crypt distortion Colitis severity was estimated by disease activity that was graded as absent, mild, moderate and marked

Material and Methods Assessment of mucosal immunophenotype by examination of the inflammatory infiltrate, including semiquantitative immunohistochemical characterization of lymphocytic subsets (CD20, CD3, CD4, CD8) by measuring the relative mrna expression for transcription factors and cytokines specific for Teff and Treg by real-time RT-PCR in biopsy-tissue specimens obtained during endoscopy

Results Histological characteristics Colitis: diffuse chronic active (6 cases/67%), patchy chronic active (2 cases/22%) and focally active (1 case/11%) Activity: mild (1 case/11%), moderate (5 cases/56%) and severe (3 cases/33%) Ulcerations and/or erosions (8 cases/89%)

Results Histological characteristics Cryptitis usually mild (8 cases/89%) Small and high numbers of crypt abscesses in 4 and 3 cases respectively Crypts with mucin depleted cell lining appearing thinned and elongated in sagittal sections almost constantly present (8 cases/89%) Neutrophils from small up to high numbers invariably present

Results Immunohistochemical characterization of the lymphocytic population Small number of B (CD20 +) lymphocytes Moderate or high number of T (CD3 +) lymphocytes High CD4/CD8 ratio CD4 CD20 CD3 CD4 CD8

Table 4. Histological characteristics of ipilimumab-associated colitis case Distribution /severity Infiltrate L P E N cryptitis crypt abscess Erosion /ulceration crypt mucin depletion /flattening crypt distortion subtype CD 20 CD 3 CD 8 CD 4 1 Patchy/ severe +++ ++ +++ - + + + yes yes no CD-like 2 Diffuse/ moderate ++ ++ +++ - + + ++ yes yes no CD-like + +++ ++ +++ 3 focal active/ mild ++ ++ ++ + + + + no no no CD-like + ++ + +++ 4 Diffuse severe +++ +++ ++ + + + - yes yes yes UC-like + +++ ++ +++ 5 Diffuse/ moderate ++ ++ +++ - ++ ++ + yes yes no UC-like + ++ + +++ 6 Diffuse/ moderate ++ ++ +++ - + + + yes yes no UC-like + ++ ++ ++ 7 Diffuse/ moderate ++ +++ ++ ++ ++ ++ ++ yes yes no IC + ++ - +++ + ++ - +++ 8 Patchy severe +++ ++ +++ ++ ++ + ++ yes yes yes IC + ++ + ++ - +++ 9 Diffuse/ moderate ++ +++ ++ - + - - yes yes no IC + ++ + ++ L, lymphocytes; P, plasma cells; E, eosinophils; N, neutrophils; CD, Crohn s disease; UC, ulcerative colitis; IC, intermediate colitis

Results Colonic mrna expression of cytokines and transcription factors The expression of the major Th1 and Th17 cytokines, IFN-γ and IL-17, highly upregulated IFN-γ expression >10-fold and IL-17A >5-fold upregulated compared to baseline control No significant changes in the expression of the major Th2 cytokines, IL-4 and IL-13 Clancy, S. & Brown, W. (2008) Translation: DNA to mrna to Protein. Nature Education 1(1):101

Results Colonic mrna expression of cytokines and transcription factors Increased mucosa expression of both the Treg-specific transcription factor FoxP3 and the major Treg cytokine IL-10 The TNF like cytokine, TL1A (TNFSF15) highly upregulated in both IBD and IAC The functional receptor DR3 (TNFRSF25) specifically upregulated in IAC Clancy, S. & Brown, W. (2008) Translation: DNA to mrna to Protein. Nature Education 1(1):101

Results are expressed as mean ± SEM. * indicate statistically significant differences in comparison to healthy control baseline expression.

Conclusions The histological spectrum of IAC is consistent with IBD-like colitis Prominent neutrophilic infiltrations, no crypt distortion as well as the presence of crypts with flattened, mucin depleted epithelium speak in favor of ipilimumab-inflicted colitis in consideration with the clinical history

Conclusions The highly upregulated mucosal Th1/IFN-γ and Th17/IL-17A responses combined with heavy infiltration of the lamina propria with CD4+ cells support the hypothesis that CTLA-4 blockade may lead to unrestricted lymphocytic activation and exaggerated effector proinflammatory pathways Increased mucosa IL-17A produced by effector Th17 cells may drive the increased numbers of neutrophils observed in IAC

Conclusions We support the similarity between IAC and IBD, by showing that the two conditions share similar histology, inflammatory mucosal signatures, dominated by exaggerated Th1 and Th17 responses as well as ineffective upregulation of FoxP3 and IL-10

Thank you for your attention!